Dual Antiplatelet Therapy
Three months may be the ‘sweet spot’ for dual antiplatelet therapy after PCI
CHICAGO — Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low and high bleeding risk, compared with 1 and 12 months of DAPT, according to new data.
Acute coronary syndrome guideline includes updates on blood thinners, circulatory support
The American College of Cardiology and American Heart Association issued updated practice guidelines for the management of patients with acute coronary syndrome.
At Issue: Debate over DAPT duration endures
Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual antiplatelet therapy should last after PCI.
The year in thrombosis, CAD: New PCI populations and DAPT strategies
Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top developments in thrombosis and coronary disease from 2024.
Delayed dual antiplatelet therapy significantly reduces new stroke occurrence at 90 days
Initiating dual antiplatelet therapy within 72 hours of symptom onset in patients with ischemic stroke or transient ischemic attack led to a significant reduction in new stroke occurrence at 90 days, according to results of a subgroup analysis.
De-escalation strategy may be preferred to 12-month DAPT in PCI with drug-coated balloon
In patients with ACS who underwent PCI with a drug-coated balloon, an antiplatelet therapy de-escalation strategy was noninferior to 12-month dual antiplatelet therapy, researchers reported at EuroPCR.
Long-term DAPT may not be needed for patients with ACS after angioplasty, stenting
ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.
Switch to ticagrelor monotherapy after 3-month DAPT safely reduces bleeding after PCI
SAN FRANCISCO — In a new meta-analysis, researchers reaffirmed safety and efficacy of ticagrelor monotherapy to reduce major bleeding after 3-month dual antiplatelet therapy among patients who underwent PCI for ACS.
Stopping aspirin 1 month after drug-eluting stent implantation feasible for patients with ACS
SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy.
Extended clopidogrel strategy prevents adverse events in ‘bi-risk’ patients with ACS
Extended clopidogrel monotherapy after 9-to-12-month dual antiplatelet therapy reduced risk for adverse events in patients with ACS at increased bleeding and ischemic risk who underwent drug-eluting stent implantation, a speaker reported.